Compare Cytokinetics Inc (CYTK) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Monster Beverage Corp — how do they compare? Cytokinetics Inc trades at $81.96 (market cap $11.12B), while Monster Beverage Corp trades at $98.03 (market cap $95.85B). The key difference: Monster Beverage Corp is far larger — about 8.6× Cytokinetics Inc's market cap. Which is the better fit depends on your goals.
| CYTK | MNST | |
|---|---|---|
Market Cap | $11.12B | $95.85B |
Sector | Technology | Consumer Staples |
52-Week High | $87.26 | $98.01 |
52-Week Low | $33.23 | $58.65 |
Enterprise Value | $11.59B | $94.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Monster Beverage (MNST) trades at $97.07, down 0.33% on the day, with strong technical bullish signals from moving averages and a neutral RSI. The company demonstrates robust fundamentals with 2025 revenue of $8.29B, net income of $1.91B, and consistent earnings beats. Recent corporate actions include a 2-for-1 stock split effective August 11, 2026, reflecting management confidence in continued growth prospects.
MNST presents a compelling growth story with accelerating international expansion and product innovation driving market share gains. However, premium valuation multiples (P/E 46.89, P/S 10.89) create vulnerability to earnings disappointments. Analyst consensus remains positive with 53% buy ratings, though the $94.60 price target suggests limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
